Startup profile · funding coverage
Truemed funding, valuation and investors
Lets consumers use HSA/FSA funds on evidence-based preventive health products via Letters of Medical Necessity.
Keep track of Truemed
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$34M · December 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$34M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Overview
Truemed enables consumers to purchase eligible preventive health and wellness products using tax-advantaged HSA and FSA funds. The company partners with merchants and facilitates Letters of Medical Necessity (LMNs) from licensed providers where regulations require documentation. In December 2025, Andreessen Horowitz Bio + Health led a $34M Series A with Bessemer Venture Partners and Box Group participating. Truemed reported more than 3,000 merchant partners and approximately 3x year-over-year revenue growth entering the round. The company sits at the intersection of consumer wellness commerce and healthcare payment compliance.
Why Truemed is interesting
Preventive spend is mostly post-tax — a16z Bio+Health led $34M Series A as Truemed hit 3,000+ merchant partners and 3x YoY revenue.
Product & use cases
Truemed checkout and API let qualified wellness purchases process through HSA/FSA payment rails after appropriate medical necessity documentation — embedded at merchant checkout.
- Consumers buying gym, sleep, and nutrition products with HSA/FSA dollars
- Merchants increasing conversion by accepting tax-advantaged payments
- Employers enhancing preventive benefits without changing core health plans
Key facts
- Series A (Dec 2025): $34M led by a16z Bio+Health; Bessemer, BoxGroup participated (PR Newswire)
- 3,000+ merchant partners; ~3x YoY revenue growth cited (a16z)
- HSA/FSA payments for evidence-based preventive health products
- Letter of Medical Necessity workflow for eligible purchases
Funding history (newest first)
Investors in our directory
Funds linked from Truemed's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Merchant network scale (3,000+ partners) plus compliance workflow for LMNs — hard to replicate quickly for new entrants.
HSA/FSA rules are complex and change-sensitive. Truemed's growth depends on merchant ROI proof and regulatory clarity on eligible preventive categories.
-
Flex (HSA/FSA payments) direct
Competing HSA/FSA checkout integrations.
-
Traditional HSA administrators incumbent
Bank-held HSAs without merchant-embedded checkout.
-
Post-tax wellness spend alternative
Default consumer behavior Truemed tries to shift.
Notable stories
- Truemed turned tax-advantaged HSAs into a growth lever for DTC wellness brands — a16z Bio+Health led Series A at 3,000 merchants when most shoppers still paid post-tax (PR Newswire, Dec 2025).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Truemed's financing or category context.
FAQs about Truemed
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.